Australia markets open in 4 hours 52 minutes

Verrica Pharmaceuticals Inc. (1NE.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
8.62-0.10 (-1.09%)
As of 08:01AM CEST. Market open.
Currency in EUR

Valuation measures4

Market cap (intra-day) 372.99M
Enterprise value 350.72M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)48.79
Price/book (mrq)264.75
Enterprise value/revenue 42.47
Enterprise value/EBITDA -10.19

Trading information

Stock price history

Beta (5Y monthly) 1.83
52-week change 358.55%
S&P500 52-week change 326.16%
52-week high 38.72
52-week low 32.60
50-day moving average 35.75
200-day moving average 34.63

Share statistics

Avg vol (3-month) 38
Avg vol (10-day) 348
Shares outstanding 542.42M
Implied shares outstanding 642.77M
Float 815.05M
% held by insiders 139.07%
% held by institutions 141.76%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-486.12%

Management effectiveness

Return on assets (ttm)-69.22%
Return on equity (ttm)-243.35%

Income statement

Revenue (ttm)8.91M
Revenue per share (ttm)0.19
Quarterly revenue growth (yoy)10,240.50%
Gross profit (ttm)N/A
EBITDA -74.05M
Net income avi to common (ttm)-80.74M
Diluted EPS (ttm)-1.64
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)48.94M
Total cash per share (mrq)1.15
Total debt (mrq)46.44M
Total debt/equity (mrq)3,079.84%
Current ratio (mrq)3.17
Book value per share (mrq)0.04

Cash flow statement

Operating cash flow (ttm)-53.93M
Levered free cash flow (ttm)-27.93M